Clinical Trial Update: Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating topiramate for cryptogenic sensory peripheral neuropathy in metabolic syndrome has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome

Drugs mentioned

• Topiramate (Topiramate)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2023-11-14